Bone Marrow Cancer

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Bone Marrow Cancer

MalaCards integrated aliases for Bone Marrow Cancer:

Name: Bone Marrow Cancer 12 15
Malignant Neoplasm of Bone Marrow 12 71
Chronic Myeloproliferative Disorder 71
Myeloproliferative Disorders 43
Malignant Bone Marrow Tumor 12
Myeloproliferative Disease 71
Bone Marrow Neoplasms 71
Bone Marrow Neoplasm 12
Bone Marrow Tumor 12


External Ids:

Disease Ontology 12 DOID:4960
MeSH 43 D009196
SNOMED-CT 67 414794006
ICD10 32 D47.1
UMLS 71 C0027022 C0282609 C1292778 more

Summaries for Bone Marrow Cancer

Disease Ontology : 12 A hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow.

MalaCards based summary : Bone Marrow Cancer, also known as malignant neoplasm of bone marrow, is related to myeloproliferative neoplasm and myelodysplastic/myeloproliferative neoplasm. An important gene associated with Bone Marrow Cancer is U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), and among its related pathways/superpathways are MicroRNAs in cancer and Innate Lymphoid Cells Differentiation. The drugs Hydroxyurea and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid.

Wikipedia : 74 Multiple myeloma (MM), also known as plasma cell myeloma and simple myeloma, is a cancer of plasma... more...

Related Diseases for Bone Marrow Cancer

Diseases related to Bone Marrow Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 549)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 34.8 U2AF1 MIR28 MIR17 MIR126 LUC7L2 JAK2
2 myelodysplastic/myeloproliferative neoplasm 33.3 U2AF1 LUC7L2 JAK2
3 ocular cancer 32.8 U2AF1 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
4 myelodysplastic syndrome 32.8 U2AF1 MIR34A LUC7L2 JAK2 H2AC18 CD34
5 diamond-blackfan anemia 32.0 U2AF1 LUC7L2 JAK2 CD34
6 chronic myelomonocytic leukemia 31.9 U2AF1 LUC7L2 JAK2 H2AC18
7 leukemia, acute myeloid 31.6 U2AF1 MIR9-1 MIR34A MIR28 MIR21 MIR199A1
8 chronic neutrophilic leukemia 31.6 U2AF1 LUC7L2 JAK2 CD34
9 atypical chronic myeloid leukemia 31.4 U2AF1 LUC7L2 JAK2
10 leukemia, acute lymphoblastic 31.3 U2AF1 MIR9-1 MIR21 MIR199A1 MIR17 MIR142
11 megakaryocytic leukemia 31.2 U2AF1 KDM4C JAK2
12 chronic leukemia 31.2 U2AF1 LUC7L2 KDM4C JAK2 H2AC18 CD34
13 b-cell lymphoma 31.2 MIR34A MIR21 MIR17 MIR142 JAK2 IRF4
14 severe combined immunodeficiency 31.1 IRF4 ICOSLG H2AC18 CD34 CCR6
15 vascular disease 31.1 MIR21 MIR199A1 MIR145 MIR126 MIR125A CD34
16 leukemia, chronic lymphocytic 31.0 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR17
17 deficiency anemia 31.0 U2AF1 JAK2 H2AC18 CD34
18 lymphoma, hodgkin, classic 31.0 MIR21 KDM4C JAK2 IRF4 ICOSLG CCR6
19 neutrophilia, hereditary 30.9 U2AF1 LUC7L2 JAK2
20 heart septal defect 30.8 U2AF1 MIR199A1 MIR17 H2AC18
21 monoclonal gammopathy of uncertain significance 30.8 U2AF1 MIR126 LUC7L2 IRF4 ICOSLG CCR6
22 myeloid sarcoma 30.8 U2AF1 IRF4 CD34
23 aortic valve disease 2 30.8 MIR34A MIR21 MIR199A1 MIR17 MIR126
24 autosomal recessive disease 30.8 U2AF1 MIR9-1 KDM4C IRF4 ICOSLG H2AC18
25 intermediate coronary syndrome 30.8 MIR145 MIR142 MIR126
26 blood platelet disease 30.8 U2AF1 LUC7L2 JAK2 ICOSLG H2AC18 CD34
27 exanthem 30.8 ICOSLG H2AC18 CCR6
28 mycobacterium tuberculosis 1 30.7 MIR21 ICOSLG H2AC18 CCR6
29 skin disease 30.7 U2AF1 MIR21 MIR199A1 MIR17 MIR142 MIR126
30 diffuse large b-cell lymphoma 30.7 MIR28 MIR21 MIR199A1 MIR17 MIR145 MIR142
31 lymphadenitis 30.7 MIR145 ICOSLG CCR6
32 bladder cancer 30.6 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR145
33 lymphoma, non-hodgkin, familial 30.6 U2AF1 MIR9-1 MIR34A MIR28 MIR21 MIR199A1
34 systemic lupus erythematosus 30.6 MIR21 MIR142 MIR125A JAK2 IRF4 ICOSLG
35 diabetes mellitus, noninsulin-dependent 30.6 MIR28 MIR21 MIR199A1 MIR17 MIR142 MIR126
36 leukemia, chronic myeloid 30.5 U2AF1 MIR9-1 MIR199A1 MIR17 MIR142 MIR126
37 arteries, anomalies of 30.5 MIR9-1 MIR34A MIR28 MIR21 MIR199A1 MIR17
38 sm-ahnmd 30.5 U2AF1 JAK2
39 ovarian cancer 30.5 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR145
40 myeloma, multiple 30.3 U2AF1 MIR9-1 MIR28 MIR26A1 MIR21 MIR199A1
41 hematologic cancer 30.3 U2AF1 MIR9-1 MIR34A MIR28 MIR21 MIR199A1
42 myeloproliferative disorder, chronic, with eosinophilia 12.8
43 pdgfrb-associated chronic eosinophilic leukemia 11.8
44 polycythemia vera 11.8
45 myelofibrosis 11.7
46 8p11 myeloproliferative syndrome 11.7
47 juvenile myelomonocytic leukemia 11.6
48 thrombocythemia 1 11.5
49 mastocytosis, cutaneous 11.5
50 budd-chiari syndrome 11.5

Graphical network of the top 20 diseases related to Bone Marrow Cancer:

Diseases related to Bone Marrow Cancer

Symptoms & Phenotypes for Bone Marrow Cancer

Drugs & Therapeutics for Bone Marrow Cancer

Drugs for Bone Marrow Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 382)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Hydroxyurea Approved Phase 3 127-07-1 3657
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
deoxycholic acid Approved Phase 3 83-44-3 222528
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
Idarubicin Approved Phase 3 58957-92-9 42890
Pipobroman Approved Phase 3 54-91-1 4842
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Amitriptyline Approved Phase 3 50-48-6 2160
Perphenazine Approved Phase 3 58-39-9 4748
Baclofen Approved Phase 3 1134-47-0 2284
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
Dalteparin Approved Phase 3 9005-49-6
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Acyclovir Approved Phase 3 59277-89-3 2022
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Fosaprepitant Approved Phase 3 172673-20-0 219090
Histamine Approved, Investigational Phase 3 51-45-6 774
Lenalidomide Approved Phase 3 191732-72-6 216326
Hydroxyzine Approved Phase 3 68-88-2 3658
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
Daunorubicin Approved Phase 3 20830-81-3 30323
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Thioguanine Approved Phase 3 154-42-7 2723601
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
Mycophenolic acid Approved Phase 3 24280-93-1 446541
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
Mercaptopurine Approved Phase 3 50-44-2 667490
Danazol Approved Phase 3 17230-88-5 28417
tannic acid Approved Phase 3 1401-55-4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
Polyestradiol phosphate Approved Phase 3 28014-46-2
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
45 Analgesics, Opioid Phase 3
46 Psychotropic Drugs Phase 3
47 Anti-Anxiety Agents Phase 3
48 Antipsychotic Agents Phase 3
49 Fibrinolytic Agents Phase 3
50 Amebicides Phase 3

Interventional clinical trials:

(show top 50) (show all 568)
# Name Status NCT ID Phase Drugs
1 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
3 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
4 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
5 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
6 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
7 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
8 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
10 Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2) Completed NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
11 An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Completed NCT02292446 Phase 3 Ruxolitinib
12 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
13 A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
14 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
15 A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo;Pomalidomide
16 An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
17 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
18 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
19 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
22 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
23 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
24 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
25 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
26 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
27 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
28 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
29 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
30 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes Completed NCT01381809 Phase 3 Group 2: Placebo;Group 1: Epoetin alfa
31 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
32 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
33 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
34 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
35 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
36 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
37 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
38 A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2) Recruiting NCT03859427 Phase 3 Carfilzomib;Carfilzomib;Lenalidomide;Dexamethasone
39 Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression Recruiting NCT03480360 Phase 3 Cyclophosphamide;Fludarabine;Tacrolimus;cellcept;g-csf
40 Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus. Recruiting NCT03808805 Phase 3 Aprepitant 80 mg;Hydroxyzine 25mg;Placebo of Hydroxyzine;Placebo of Aprepitant
41 The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation Recruiting NCT03640325 Phase 3
42 Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
43 A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis Recruiting NCT04173494 Phase 3 Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol
44 A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials. Recruiting NCT04064060 Phase 3 Luspatercept
45 Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome Recruiting NCT02521493 Phase 3 Asparaginase;Asparaginase Erwinia chrysanthemi;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone;Mitoxantrone Hydrochloride;Thioguanine
46 A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib Active, not recruiting NCT02627677 Phase 3 ponatinib 30 mg QD;ponatinib 15 mg QD;nilotinib 400 mg BID
47 PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant Active, not recruiting NCT01366612 Phase 3 Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
48 An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 and Standard First Line Treatment (BAT) in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
49 Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Fludarabine-Melphalan Versus Fludarabine-Melphalan-ATG Reduced-intensity Conditioning: a Phase III Randomized Study From the Belgian Hematology Society (BHS) Suspended NCT03852407 Phase 3 Thymoglobulin;Melphalan;Fludarabine
50 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate

Search NIH Clinical Center for Bone Marrow Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Sodium phenylbutyrate

Cochrane evidence based reviews: myeloproliferative disorders

Genetic Tests for Bone Marrow Cancer

Anatomical Context for Bone Marrow Cancer

MalaCards organs/tissues related to Bone Marrow Cancer:

Bone, Bone Marrow, Myeloid, T Cells, Breast, Liver, Testes

Publications for Bone Marrow Cancer

Articles related to Bone Marrow Cancer:

(show all 37)
# Title Authors PMID Year
Proteasome inhibition in multiple myeloma: lessons for other cancers. 61
31875696 2020
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. 61
32139017 2020
Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. 61
31256359 2020
Exploration of quinolone and quinoline derivatives as potential anticancer agents. 61
31410781 2019
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. 61
31217335 2019
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. 61
30679915 2019
Persistent Exposure to Fusobacterium nucleatum Triggers Chemokine/Cytokine Release and Inhibits the Proliferation and Osteogenic Differentiation Capabilities of Human Gingiva-Derived Mesenchymal Stem Cells. 61
31921705 2019
Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. 61
29872115 2018
Distinctive inhibition of alkaline phosphatase isozymes by thiazol-2-ylidene-benzamide derivatives: Functional insights into their anticancer role. 61
29363794 2018
Detailed investigation of anticancer activity of sulfamoyl benz(sulfon)amides and 1H-pyrazol-4-yl benzamides: An experimental and computational study. 61
29763580 2018
Readmissions After Surgical Resection of Metastatic Tumors of the Spine at a Single Institution. 61
28254537 2017
Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation. 61
28492285 2017
Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. 61
28122281 2017
Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle. 61
27159504 2017
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. 61
27809856 2016
A Personalized Framework for Dynamic Modeling of Disease Trajectories in Chronic Lymphocytic Leukemia. 61
26929022 2016
Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. 61
27569215 2016
Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells. 61
26204324 2016
Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. 61
25218571 2014
Mayo breakthrough: virus may destroy bone marrow cancer. 61
25233543 2014
A case of multiple myeloma presenting as scalp swelling with intracranial extension. 61
24347954 2013
Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. 61
22879387 2012
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 61
22696376 2012
Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. 61
22395247 2012
The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding. 61
21804610 2012
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases. 61
22970388 2012
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 61
21901718 2011
Hematological and toxicological evaluation of formaldehyde as a potential cause of human leukemia. 61
20729258 2011
Future novel single agent and combination therapies. 61
20010171 2009
Seleno-L-Methionine Modulation of Nucleotide Excision DNA Repair Relevant to Cancer Prevention and Chemotherapy. 61
20336178 2009
The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. 61
19342998 2009
Thalidomide in multiple myeloma. 61
16433584 2006
Gene therapy in pediatric surgery. 61
8858767 1996
Bone marrow chromosome abnormalities in breast cancer in patients following adjuvant chemotherapy. 61
7471052 1980
Erythrokinetics and androgens in bone marrow cancer. 61
975001 1976
[Heterogeneity of immunoreactive calcitonin in the plasma of patients with bone marrow cancer]. 61
772524 1975
[Relation between multiple myeloma (Rusticki-Kaller disease) & metastatic bone marrow cancer based on 2 personal case reports]. 61
13587007 1957

Variations for Bone Marrow Cancer

Expression for Bone Marrow Cancer

Search GEO for disease gene expression data for Bone Marrow Cancer.

Pathways for Bone Marrow Cancer

Pathways related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 MIR9-1 MIR34A MIR28 MIR26A1 MIR21 MIR199A1
2 11.03 IRF4 CD34 CCR6
3 10.27 MIR199A1 MIR145

GO Terms for Bone Marrow Cancer

Cellular components related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MIR28 MIR26A1 MIR21 MIR199A1 MIR17 MIR142
2 extracellular vesicle GO:1903561 9.1 MIR34A MIR26A1 MIR21 MIR17 MIR126 MIR125A

Biological processes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 MIR34A MIR21 MIR125A KDM4C CD34
2 positive regulation of inflammatory response GO:0050729 9.73 MIR21 MIR126 JAK2
3 positive regulation of angiogenesis GO:0045766 9.73 MIR21 MIR199A1 MIR126 CD34
4 negative regulation of cell migration GO:0030336 9.71 MIR9-1 MIR34A MIR26A1 MIR21
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 MIR21 MIR126 JAK2
6 negative regulation of angiogenesis GO:0016525 9.67 MIR34A MIR21 MIR145 MIR125A
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MIR26A1 MIR21 MIR17 JAK2
8 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR199A1 MIR17
9 positive regulation of connective tissue replacement GO:1905205 9.57 MIR34A MIR199A1
10 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.56 MIR21 MIR199A1 MIR145 JAK2
11 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.55 MIR26A1 MIR125A
12 miRNA mediated inhibition of translation GO:0035278 9.55 MIR9-1 MIR28 MIR21 MIR17 MIR145
13 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.54 MIR21 MIR125A
14 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.51 MIR199A1 MIR17
15 positive regulation of metalloendopeptidase activity GO:1904685 9.48 MIR21 MIR17
16 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.46 MIR21 MIR17
17 gene silencing by miRNA GO:0035195 9.36 MIR9-1 MIR34A MIR28 MIR26A1 MIR21 MIR199A1
18 negative regulation of vascular endothelial growth factor production GO:1904046 9.26 MIR34A MIR199A1 MIR17 MIR125A

Molecular functions related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR9-1 MIR34A MIR28 MIR26A1 MIR21 MIR199A1
2 mRNA 3'-UTR binding GO:0003730 9.33 MIR28 MIR21 MIR125A
3 RNA polymerase II complex binding GO:0000993 9.13 MIR145 MIR126 MIR125A

Sources for Bone Marrow Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....